24-Jun-2026
PRNewswire (Tue, 9-Jun 5:54 PM ET)
PRNewswire (Thu, 4-Jun 4:20 PM ET)
PRNewswire (Mon, 1-Jun 4:50 PM ET)
Globe Newswire (Thu, 28-May 4:20 PM ET)
PRNewswire (Thu, 28-May 9:19 AM ET)
Globe Newswire (Wed, 27-May 4:20 PM ET)
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
Globe Newswire (Wed, 27-May 9:00 AM ET)
Globe Newswire (Wed, 27-May 8:00 AM ET)
Globe Newswire (Tue, 26-May 8:00 AM ET)
Globe Newswire (Fri, 22-May 10:09 AM ET)
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Pacira Biosciences trades on the NASDAQ stock market under the symbol PCRX.
As of June 24, 2026, PCRX stock price climbed to $23.96 with 405,549 million shares trading.
PCRX has a beta of 0.59, meaning it tends to be less sensitive to market movements. PCRX has a correlation of 0.03 to the broad based SPY ETF.
PCRX has a market cap of $942.18 million. This is considered a Small Cap stock.
Last quarter Pacira Biosciences reported $177 million in Revenue and $.60 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.08.
In the last 3 years, PCRX traded as high as $40.73 and as low as $11.16.
The top ETF exchange traded funds that PCRX belongs to (by Net Assets): IJR, VTI, IWM, VB, AVUV.
PCRX has underperformed the market in the last year with a return of -3.2%, while the SPY ETF gained +23.4%. In the last 3 month period, PCRX fell short of the market, returning +5.8%, while SPY returned +12.2%. However, in the most recent 2 weeks PCRX has outperformed the stock market by returning +3.2%, while SPY returned -0.3%.
PCRX support price is $22.85 and resistance is $24.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PCRX shares will trade within this expected range on the day.
